Provectus Biopharmaceuticals Announces Publication of Preclinical Data of Oral Administration of Provectus Rose Bengal for Solid Tumor Cancers
April 18, 2024 08:00 ET
|
Provectus Biopharmaceuticals Inc.
Research on breast, colorectal, head and neck, and testicular cancersNovel downregulation of WNK1 and Wnt signaling KNOXVILLE, TN, April 18, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals,...
BioNTech präsentiert auf ESMO-Kongress weitere ermutigende Daten aus Phase-1/2-Studie mit CAR-T-Programm BNT211 in schwer zu behandelnden soliden Tumoren
September 09, 2022 10:30 ET
|
BioNTech SE
Follow-up-Daten zeigen ermutigende Anzeichen für eine klinische Anti-Tumor-Aktivität sowie ein kontrollierbares Sicherheits- und Verträglichkeitsprofil; Daten bauen auf den positiven...
BioNTech Presents Encouraging Phase 1/2 Follow-up Data for CAR-T Candidate BNT211 in Hard-To-Treat Solid Tumors at ESMO
September 09, 2022 10:30 ET
|
BioNTech SE
Follow-up data further demonstrate encouraging signs of clinical anti-tumor activity and a manageable safety and tolerability profile, building on the positive interim data presented at AACR in...
BioNTech erhält Priority-Medicines (PRIME)-Status der EMA für verstärkte regulatorische Unterstützung des CAR-T-Kandidaten BNT211 zur Behandlung von Hodenkrebs
June 23, 2022 11:00 ET
|
BioNTech SE
Erster BioNTech-Produktkandidat, der von der Europäischen Arzneimittelagentur den Priority-Medicines (PRIME)-Status erhält; dies ermöglicht eine verstärkte regulatorische Unterstützung bei der...
BioNTech Receives Priority Medicines (PRIME) Designation from EMA for Enhanced Regulatory Support of CAR-T Candidate BNT211 in Testicular Cancer
June 23, 2022 11:00 ET
|
BioNTech SE
First BioNTech product candidate to receive priority medicines (PRIME) designation by the European Medicines Agency for enhanced regulatory support facilitating the clinical development of the...
Provectus Biopharmaceuticals Announces Presentation of Multiple Protein Kinase Signaling Targets, including WNK1, for PV-10® Immunotherapy at American Association for Cancer Research (AACR) 2022 Annual Meeting
April 11, 2022 07:30 ET
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, April 11, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that preclinical research on systemic administration of investigational cancer immunotherapy PV-10 (rose...
Provectus Biopharmaceuticals Announces Publication of In Vitro Data from Research on Oral Delivery of PV-10® at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
June 09, 2021 07:00 ET
|
Provectus Biopharmaceuticals Inc.
— PV-10 treatment induced autophagic cell death in all breast, colorectal, head and neck, and testicular cancer cell lines tested — Represents prerequisite in vitro data for clinical testing...
New Alliances Push Inspire's Growth to 100 Partners, 750,000 Patients and Caregivers
May 11, 2016 07:00 ET
|
Inspire
ARLINGTON, VA--(Marketwired - May 11, 2016) - Inspire, the leading social network for health, has added new nonprofit patient advocacy organizations -- including one focused on cancer...